U.S. FDA clears LensAR ophthalmic laser system for additional utility
Ophthalmic laser system maker LensAR (Orlando, FL) has received U.S. FDA clearance for the its LENSAR Laser System with Streamline IV, expanding the platform's capabilities to include the creation of the corneal pockets and flaps used in ophthalmic procedures for treating presbyopia.
Related: FDA clears open-architecture advancements for LensAR ophthalmology laser
The presbyopia procedure features of the LENSAR Laser System with Streamline IV include a new curved contact patient interface device that enables the creation of corneal pockets and flaps without compromising patient comfort.
The new presbyopia procedure capabilities will be rolling out to LensAR users in the U.S. in 2018. The company has applied for regulatory approval in the EU and anticipates availability of the new features there later in 2018, pending approval.
For more information, please visit www.lensar.com.
BioOptics World Editors
We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)